Recent clinical trials have shown that SGLT2 inhibitors exhibit cardio-renal protective properties in patients with diabetes mellitus and diabetic kidney disease (DKD) [3, 4]. This evidence concerns the gene SLC5A2 and diabetic kidney disease.